NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company said site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.
This development is significant because NV-387 is a broad-spectrum antiviral candidate that has also been proposed for evaluation against Ebola virus infections. The company noted that the shipment makes the drug locally available should it be utilized in response efforts. NanoViricides believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.
The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. According to the press release, the company is focused on advancing NV-387 into Phase II human clinical trials.
NanoViricides is a clinical stage company that creates special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company also has other drug candidates, including NV-HHV-1 for Shingles, and NV-CoV-2 and NV-CoV-2-R for COVID-19.
The implications of this announcement extend beyond MPox. If NV-387 proves safe and effective, it could serve as a treatment for Ebola and other viral diseases, addressing significant unmet medical needs in regions like the DRC, which faces outbreaks of both MPox and Ebola. Moreover, NV-387's broad-spectrum activity could make it a valuable tool in pandemic preparedness.
For more information about NanoViricides, visit the company's website. Latest news and updates relating to NNVC are available in the company's newsroom.
